Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

NCT05248997 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Interventions

DRUG: rimegepant 75 mg ODT
DRUG: Matching placebo

Sponsor

Pfizer